March 26, 2019

NCCN Updates Ovarian Cancer Guidelines

By

The NCCN has recently updated its ovarian cancer treatment guidelines and make the following significant changes.

  • All patients with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer should have a genetic risk evaluation and BRCA1/2 testing performed.
  • Maintenance Therapy:
    • Lynparza (olaparib) was added as a maintenance therapy option after complete or partial clinical remission following primary therapy – with or without Avastin (bevacizumab) for BRCA1/2 mutations
    • Avastin was added as a maintenance therapy option for stable disease following treatment with Avastin.
  • Systemic therapy section, three treatment regimens have been added as options for the treatment of recurrent platinum-sensitive disease
    • carboplatin plus liposomal doxorubicin and bevacizumab (preferred regimen)
    • irinotecan plus cisplatin (useful in certain circumstances, for clear cell carcinoma)
    • fulvestrant (useful in certain circumstances, for low-grade serous carcinoma).
  • Three regimens were added to the acceptable recurrence therapy options for platinum-resistant disease:
    • Oral cyclophosphamide plus bevacizumab (preferred regimen)
    • sorafenib plus topotecan
    • Fulvestrant (useful in certain circumstances, for low-grade serous carcinoma).

https://www.journalofclinicalpathways.com/news/nccn-updates-clinical-practice-guideline-ovarian-cancer?hmpid=Q0hXRUFWRVJAQ0FOQ0VSQ09OU1VMVEFOVFMuQ09N

Copyright © 2019 CancerConnect. All Rights Reserved.

Tags: News, Ovarian Cancer, Uncategorized